

INITIAL STATEMENT OF BENEFICIAL OWNERSHIP OF SECURITIES

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL	
OMB Number:	3235-0104
Estimated average burden hours per response:	0.5

1. Name and Address of Reporting Person* <u>Kleczynski Robert A</u>			2. Date of Event Requiring Statement (Month/Day/Year) 06/30/2023		3. Issuer Name and Ticker or Trading Symbol <u>EXELON CORP [EXC]</u>	
(Last)	(First)	(Middle)	4. Relationship of Reporting Person(s) to Issuer (Check all applicable) Director <input type="checkbox"/> 10% Owner <input type="checkbox"/> <input checked="" type="checkbox"/> Officer (give title below) <input type="checkbox"/> Other (specify below) <u>SVP & Corp Controller</u>			5. If Amendment, Date of Original Filed (Month/Day/Year)
10 S DEARBORN STREET 54TH FLOOR						
(Street)	(City)	(State)	(Zip)			
CHICAGO	IL	60603				
(City)	(State)	(Zip)				6. Individual or Joint/Group Filing (Check Applicable Line) <input checked="" type="checkbox"/> Form filed by One Reporting Person <input type="checkbox"/> Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Beneficially Owned

1. Title of Security (Instr. 4)	2. Amount of Securities Beneficially Owned (Instr. 4)	3. Ownership Form: Direct (D) or Indirect (I) (Instr. 5)	4. Nature of Indirect Beneficial Ownership (Instr. 5)
Common Stock	17,068	D	

Table II - Derivative Securities Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)

1. Title of Derivative Security (Instr. 4)	2. Date Exercisable and Expiration Date (Month/Day/Year)		3. Title and Amount of Securities Underlying Derivative Security (Instr. 4)		4. Conversion or Exercise Price of Derivative Security	5. Ownership Form: Direct (D) or Indirect (I) (Instr. 5)	6. Nature of Indirect Beneficial Ownership (Instr. 5)
	Date Exercisable	Expiration Date	Title	Amount or Number of Shares			
Restricted Stock Unit Award (01/25/2021)	(1)	(1)	Common stock	1,348 ⁽¹⁾	(1)	D	
Restricted Stock Unit Award (01/28/2022)	(2)	(2)	Common stock	2,327 ⁽²⁾	(2)	D	
Restricted Unit Award (01/23/2023) Stock	(3)	(3)	Common stock	3,536 ⁽³⁾	(3)	D	
Restricted Stock Unit Award (02/25/2022)	(4)	(4)	Common stock	20,990 ⁽⁴⁾	(4)	D	
Deferred Compensation Phantom Share Equivalents	(5)	(5)	Common stock	1,438 ⁽⁵⁾	(5)	D	

Explanation of Responses:

1. Remaining 1/3 increment of annual restricted stock unit (RSU) award granted in January 2021 pursuant to the Exelon Long Term Incentive Plan; each award vests in 1/3 increments on the date of the Compensation Committee's January or February meeting in the first, second and third years after the award was granted. Award balances accrue additional units through automatic dividend reinvestment, which vest on the same schedule as the underlying award.
2. Remaining 2/3 increment of annual RSU award granted in January 2022 pursuant to the Exelon Long Term Incentive Plan; each award vests in 1/3 increments on the date of the Compensation Committee's January or February meeting in the first, second and third years after the award was granted. Award balances accrue additional units through automatic dividend reinvestment, which vest on the same schedule as the underlying award.
3. Annual RSU award granted in January 2023 pursuant to the Exelon Long Term Incentive Plan; each award vests in 1/3 increments on the date of the Compensation Committee's January or February meeting in the first, second and third years after the award was granted. Award balances accrue additional units through automatic dividend reinvestment, which vest on the same schedule as the underlying award.
4. Restricted stock unit award granted pursuant to the Exelon Long Term Incentive Plan. Award balance accrues additional units through automatic dividend reinvestment and all shares will cliff vest on February 25, 2025 with each RSU representing the right to receive one share of Exelon common stock upon vesting.
5. Phantom share equivalents representing units held in the Exelon stock fund in a multi-fund, non-qualified deferred compensation plan. The Exelon stock fund is a unitized fund that consists of Exelon common stock and short-term investments. Units of the fund will be settled upon the reporting person's separation from the company for any reason. Units will be settled in cash. Units are acquired through regular periodic contributions, company matching contributions and the reinvestment of dividend equivalents. The balance of phantom share equivalents may fluctuate due to periodic changes in the fund composition.

Elizabeth M. Hensen, Attorney-in-Fact 07/03/2023
for Robert A Kleczynski

** Signature of Reporting Person

Date

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

* If the form is filed by more than one reporting person, see Instruction 5 (b)(v).

** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

EXELON
Section 16 Report

The undersigned hereby constitutes and appoints M. Hensen, Melissa E. Ramirez or Tom Boins as attorney-in-fact to:

- (1) execute for and on behalf of the undersigned as a director of Exelon Corporation (“*Exelon*”) all documents required by Section 16(a) of the Securities Exchange Act of 1934 (including EDGAR Form ID, Forms 16(a) and *Reports*”);
- (2) do and perform any and all acts for and on behalf of the undersigned as desirable to complete and execute the undersigned’s amendment or amendments thereto to the Securities and Exchange Commission’s Form 16(a) and *Reports*;
- (3) take any other action of any type or kind that, in the opinion of such attorney-in-fact, may be necessary or advisable, by, the undersigned, it being understood that the undersigned, on behalf of the undersigned pursuant to this power of attorney, contain such terms and conditions as may be deemed appropriate in fact’s discretion.


The undersigned hereby grants to each such any and every act and thing whatsoever req of the rights and powers herein granted, as could do if personally present, with full confirming all that such attorney-in-fact, lawfully do or cause to be done by virtue granted. The undersigned acknowledges th at the request of the undersigned, are not responsibilities to comply with Section 16 o

This Power of Attorney shall remain in full f file Section 16 Reports with respect to the u by Exelon, unless earlier revoked by the attorneys-in-fact.

IN WITNESS WHEREOF, the undersigne as of this 11th day of October 2022.

By:

Name: Jeanne M Jones

A handwritten signature in black ink, appearing to read "Jeanne M Jones", is written over a solid horizontal line. The signature is cursive and stylized.

